Looking back over the last 40 years at FDA (as I have), there are three characteristics that create a more progressive environment at the agency: continuity of leadership, presidential support, and increased funding. For FDA in 2013 (as the saying goes): 2 out of 3 ain’t bad.

In particular, medical innovation seems poised to flourish in an FDA environment where there is continuity of policy and leadership, instead of a new team learning the ropes. I explore this and other themes in the latest issue of Pharmaphorum.com. You can read my thoughts at: http://www.pharmaphorum.com/2013/01/29/fda-post-election-continuity-and-progress-likely-to-mark-2013/.

Steven

This entry was posted on Tuesday, January 29th, 2013 at 6:51 pm and is filed under Drug Approval and Access, FDA Appropriations, FDA Leadership, Planning for FDA's Future. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.